Form 4: Fulgent Genetics CSO Sells Shares for Tax Obligations
Insider Transaction Report
Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 1,075 shares of common stock to cover tax liabilities from vested restricted stock units.
Summary
- Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock.
- The transaction involved the disposition of 1,075 shares of common stock.
- The shares were sold at a weighted-average price of $28.3318 per share, with individual transactions ranging from $28.27 to $28.38.
- The sale was executed on December 2, 2025, to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs).
- These RSUs were originally granted on February 28, 2022, and reported on a Form 4 filed on March 2, 2022.
- Following this transaction, Hanlin Gao beneficially owns 952,890 shares of common stock directly.
- The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: The filing reports a neutral event, a routine insider transaction for tax purposes, which is a common practice for executives receiving equity compensation and does not indicate a change in sentiment towards the company's prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This is a routine insider transaction for tax purposes, common for executives receiving equity compensation. It does not reflect a discretionary investment decision or provide insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minimal impact, as this is a non-discretionary sale for tax purposes and not indicative of a change in management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of original restricted stock unit (RSU) grant to the reporting person. |
| March 2, 2022 | Date the original RSU grant was reported on a Form 4 filing. |
| December 2, 2025 | Date of the reported transaction (sale of common stock). |
| December 3, 2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Fulgent Genetics, FLGT, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Hanlin Gao, Chief Scientific Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.